The use of gastrointestinal intubation studies for controlled release development
- 7 September 2009
- journal article
- review article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 68 (3), 342-354
- https://doi.org/10.1111/j.1365-2125.2009.03432.x
Abstract
This review describes clinical results of gastrointestinal intubation studies of eight controlled release (CR) candidates under development during the 1990s and offers suggestions for determining why, when and how to conduct human intubation studies. Experience with the administration of the following eight compounds to various regions of the gastrointestinal tract is described: CJ-13,610, CP-195,543, CP-331,684, CP-409,092, CP-424,391, azithromycin, sertraline, and trovafloxacin. Also included are human pharmacokinetic studies with prototype CR dosage forms for CJ-13,610 and CP-424,391. Intubation studies, while appearing invasive, are safe and not unpleasant procedures that have been found to be valuable in the development of CR formulations. The following recommendations are made regarding intubation studies: (i) no intubation study is recommended for compounds with high permeability, since these compounds are likely to be well absorbed from the colon; (ii) compounds with moderate permeability may require an intubation study if the dog colon and in silico models predict a marginally acceptable CR concentration-time profile; (iii) use a dose that approximates 1 h of the intended CR delivery rate; (iv) use the smallest volume possible; (v) define and record tubing placement; (vi) use a thermodynamically stable solution or/and suspension.This publication has 30 references indexed in Scilit:
- Dog Colonoscopy Model for Predicting Human Colon AbsorptionPharmaceutical Research, 2006
- General pharmaceutics—The new physical pharmacyJournal of Pharmaceutical Sciences, 2003
- Sertraline Pharmacokinetics and Dynamics in AdolescentsJournal of the American Academy of Child & Adolescent Psychiatry, 2002
- A Statistical Method for the Determination of Absorption Rate Constant Estimated Using the Rat Single Pass Intestinal Perfusion Model and Multiple Linear RegressionJournal of Pharmaceutical Sciences, 2002
- Efficacy of a growth hormone-releasing peptide mimetic in cardiac ischemia/reperfusion injuryEuropean Journal of Pharmacology, 2001
- Comparison of the gravimetric, phenol red, and 14C-PEG-3350 methods to determine water absorption in the rat single-pass intestinal perfusion modelAAPS PharmSci, 2001
- Growth hormone releasing peptides: growth studiesCurrent Opinion in Endocrinology, Diabetes and Obesity, 1999
- Metabolism of CP-195,543, a leukotriene B4 receptor antagonist, in the Long-Evans rat and Cynomolgus monkeyXenobiotica, 1999
- Determination of trovafloxacin, a new quinolone antibiotic, in biological samples by reversed-phase high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1996
- High-performance liquid chromatographic assay with electrochemical detection for azithromycin in serum and tissuesJournal of Chromatography B: Biomedical Sciences and Applications, 1991